Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
complex cutaneous leishmaniasis
cutaneous leishmaniasis
leishmania
liposomal amphotericin B
systemic therapy
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
05
08
2021
revised:
10
09
2021
accepted:
25
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
Sections du résumé
BACKGROUND
BACKGROUND
There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome.
METHODS
METHODS
We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included.
RESULTS
RESULTS
The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment.
CONCLUSIONS
CONCLUSIONS
L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
Identifiants
pubmed: 34684202
pii: pathogens10101253
doi: 10.3390/pathogens10101253
pmc: PMC8537943
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Acta Trop. 2011 May;118(2):87-96
pubmed: 21420925
PLoS One. 2013 Apr 29;8(4):e61843
pubmed: 23637917
Br J Dermatol. 2020 Aug;183(2):389-391
pubmed: 32078162
J Biol Chem. 2003 Sep 26;278(39):37561-8
pubmed: 12860979
Drugs. 2013 Nov;73(17):1889-920
pubmed: 24170665
Infect Dis Clin North Am. 2012 Jun;26(2):293-307
pubmed: 22632640
Euro Surveill. 2010 Mar 11;15(10):19505
pubmed: 20403308
PLoS One. 2012;7(5):e35671
pubmed: 22693548
Am J Trop Med Hyg. 2010 Nov;83(5):1028-33
pubmed: 21036832
J Clin Microbiol. 2004 Nov;42(11):5249-55
pubmed: 15528722
Am J Trop Med Hyg. 2017 Jan 11;96(1):24-45
pubmed: 27927991
Lancet Infect Dis. 2007 Jan;7(1):7
pubmed: 17182338
Cochrane Database Syst Rev. 2017 Dec 01;12:CD005067
pubmed: 29192424
Clin Infect Dis. 2010 Jan 1;50(1):80-3
pubmed: 19951107
PLoS Negl Trop Dis. 2017 Nov 20;11(11):e0006094
pubmed: 29155816
Open Forum Infect Dis. 2016 Feb 01;3(1):ofw008
pubmed: 27042675
Expert Opin Pharmacother. 2019 Jul;20(10):1251-1265
pubmed: 31063412
PLoS Negl Trop Dis. 2019 Aug 30;13(8):e0007708
pubmed: 31469834
Trop Med Int Health. 2017 Dec;22(12):1569-1578
pubmed: 29078022
Nat Rev Immunol. 2016 Sep;16(9):581-92
pubmed: 27424773
PLoS Negl Trop Dis. 2010 Dec 21;4(12):e912
pubmed: 21200420
Res Rep Trop Med. 2019 Apr 26;10:11-18
pubmed: 31118866